ATC level 4
L01FXCancer medicines (antineoplastics), subgroup L01F, subgroup L01FX
- Molecules
- 31
- Subgroups
- 25
ATC L01FX (Cancer medicines (antineoplastics), subgroup L01F, subgroup L01FX) is a level 4 group in the anatomical therapeutic chemical classification. The catalogue lists 31 molecules in it, each with brands, manufacturers and supply from India.
ATC codes are used as identifiers. Class names are written by MedsAcross and are not the WHO Collaborating Centre's text.
Subgroups
- L01FX02Gemtuzumab ozogamicin1
- L01FX03Catumaxomab1
- L01FX04Ipilimumab1
- L01FX05Brentuximab vedotin1
- L01FX06Sacituzumab govitecan5
- L01FX07Blinatumomab1
- L01FX08Elotuzumab1
- L01FX09Mogamulizumab1
- L01FX12Tafasitamab1
- L01FX13Enfortumab vedotin1
- L01FX14Polatuzumab vedotin1
- L01FX15Belantamab mafodotin1
- L01FX18Amivantamab1
- L01FX20Tremelimumab1
- L01FX22Loncastuximab tesirine1
- L01FX23Tisotumab vedotin1
- L01FX24Teclistamab1
- L01FX25Mosunetuzumab1
- L01FX26Mirvetuximab soravtansine1
- L01FX27Epcoritamab1
- L01FX28Glofitamab1
- L01FX29Talquetamab1
- L01FX31Zolbetuximab1
- L01FX33Tarlatamab1
- L01FX35Datopotamab deruxtecan1
Molecules
Molecules with an ATC code under L01FX.
- AmivantamabBiologic1 presentation1 brandL01FX18
- Belantamab mafodotinOrphan1 presentation2 brandsL01FX15
- BlinatumomabOrphan1 presentation2 brandsL01FX07
- Brentuximab vedotinOrphanCD30-directed Immunoconjugate1 presentation2 brandsL01FX05
- Catumaxomab1 brandL01FX03
- Datopotamab deruxtecanBiologic1 presentation2 brandsL01FX35
- DinutuximabOrphanGlycolipid Disialoganglioside-directed Antibody1 presentation1 brandL01FX06
- Dinutuximab betaOrphan1 brandL01FX06
- ElotuzumabOrphanAntibodies2 presentations2 brandsL01FX08
- Enfortumab vedotinBiologic1 presentation2 brandsL01FX13
- EpcoritamabOrphanBispecific CD20-directed CD3 T Cell Engager2 presentations2 brandsL01FX27
- Gemtuzumab ozogamicinOrphanCD33-directed Immunoconjugate1 presentation2 brandsL01FX02
- GlofitamabBiologicBispecific CD20-directed CD3 T Cell Engager2 presentations2 brandsL01FX28
- IpilimumabOrphanCTLA-4-directed Blocking Antibody2 presentations2 brandsL01FX04
- LinvoseltamabOrphan1 brandL01FX
- Loncastuximab tesirineOrphan1 presentation2 brandsL01FX22
- Mirvetuximab soravtansineOrphan1 presentation2 brandsL01FX26
- MogamulizumabOrphanAntibodies1 presentation2 brandsL01FX09
- MosunetuzumabOrphan4 presentations3 brandsL01FX25
- NarsoplimabOrphan1 presentation1 brandL01FX
- Polatuzumab vedotinOrphan2 presentations2 brandsL01FX14
- RamucirumabOrphanVascular Endothelial Growth Factor Receptor 2 Antagonist2 presentations2 brandsL01FG02
- RetifanlimabOrphanProgrammed Death Receptor-1 Blocking Antibody1 presentation2 brandsL01FF10
- Sacituzumab govitecanBiologic1 presentation2 brandsL01FX06
- TafasitamabOrphan1 presentation2 brandsL01FX12
- TalquetamabOrphan2 presentations2 brandsL01FX29
- TarlatamabOrphan1 presentation2 brandsL01FX33
- TeclistamabOrphan2 presentations1 brandL01FX24
- Tisotumab vedotinBiologic1 presentation2 brandsL01FX23
- TremelimumabOrphanCTLA-4-directed Blocking Antibody2 presentations2 brandsL01FX20
- ZolbetuximabOrphanClaudin 18.2-directed Cytolytic Antibody1 presentation2 brandsL01FX31
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Cannot find the medicine you need?
Our sourcing team can find unlisted, unapproved and hard-to-find medicines through licensed channels.